Lars Henning Engelholm

Title: Lars Henning Engelholm: Innovator in Antibody-Drug Conjugates

Introduction

Lars Henning Engelholm is a notable inventor based in Bagsvaerd, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 2 patents, Engelholm's work focuses on innovative solutions for targeting diseases such as cancer.

Latest Patents

Engelholm's latest patents include groundbreaking inventions related to antibody-drug conjugates targeting uPARAP. These conjugates comprise monoclonal antibodies directed against the N-terminal region of uPARAP. The invention emphasizes the delivery of active agents to cells and tissues that express uPARAP. Furthermore, it explores the use of these antibody-drug conjugates in treating diseases involving uPARAP-expressing cells, particularly cancer.

Career Highlights

Throughout his career, Engelholm has worked with esteemed institutions such as Rigshospitalet and the University of Copenhagen. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in medical research.

Collaborations

Engelholm has collaborated with notable colleagues, including Christoffer Nielsen and Niels Behrendt. These partnerships have fostered a productive environment for innovation and research in the biotechnology sector.

Conclusion

Lars Henning Engelholm is a distinguished inventor whose work in antibody-drug conjugates has the potential to revolutionize cancer treatment. His contributions to the field highlight the importance of innovation in addressing complex medical challenges.